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ABSTRACT 15 
The Notch ligand Delta-like ligand 4 (Dll4), upregulated by Vascular 16 
Endothelial Growth Factor (VEGF), is a key regulator of vessel 17 
morphogenesis and function, controlling tip and stalk cell selection during 18 
sprouting angiogenesis. Inhibition of Dll4 results in hyper-sprouting, non-19 
functional, poorly perfused vessels, suggesting a role for Dll4 in formation of 20 
mature, reactive, functional vessels, with low permeability and able to restrict 21 
fluid and solute exchange. We tested the hypothesis that Dll4 controls 22 
transvascular fluid exchange. A recombinant protein expressing only the 23 
extracellular portion of Dll4 (soluble Dll4: sDll4) induced Notch signalling in 24 
endothelial cells (EC), resulting in increased expression of VE-Cadherin, but 25 
not the tight junctional protein ZO1, at intercellular junctions. sDll4 decreased 26 
permeability of fluorescein isothiocyanate (FITC)-labelled albumin across EC 27 
monolayers and this effect was abrogated by co-culture with the γ-secretase 28 
inhibitor DAPT. One of the known molecular effectors responsible for 29 
strengthening EC-EC contacts is the cyclic AMP-dependent protein kinase A 30 
(PKA), so we tested the effect of modulation of PKA on sDll4-mediated 31 
reduction of permeability. Inhibition of PKA reversed the sDll4-mediated 32 
reduction in permeability and reduced expression of the Notch target gene 33 
Hey-1. Knockdown of PKA reduced the sDLL4 mediated VE-cadherin 34 
junctional expression. sDll4 also caused a significant decrease in the 35 
hydraulic conductivity of rat mesenteric microvessels in vivo. This reduction 36 
was abolished upon co-perfusion with the PKA inhibitor H89 dihydrochloride. 37 
These results indicate that Dll4 signalling through Notch activation acts 38 
through a cAMP/PKA pathway upon intercellular adherens junctions, but not 39 
tight junctions, to regulate endothelial barrier function. 40 
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 41 
INTRODUCTION 42 
 43 
In mature and quiescent functional vascular networks, the vessel wall forms a 44 
semi-permeable barrier, which regulates the exchange of fluid and solutes 45 
between the blood and tissues. Vascular permeability is also tightly controlled 46 
during physiological angiogenesis, in development, the female reproductive 47 
cycle and wound healing (6). Dysregulated vessel permeability is a symptom 48 
of pathologies such as cancer, diabetes and cardiovascular disease, where it 49 
results in oedema, facilitation of metastatic spread, vision loss, proteinuria and 50 
kidney failure (15, 18, 30) 51 
Vascular Endothelial Growth Factor (VEGF) is the principal mediator of the 52 
angiogenic switch and a potent inducer of vessel permeability (5, 7, 25, 40) 53 
and, as such, therapies targeting VEGF were developed to reduce 54 
permeability back to pre-pathological levels (38) (44). Administration of anti-55 
VEGF antibodies succeeded in reducing permeability in pre-clinical trials in 56 
cancer and retinal disease (26, 28), and clinical trials have demonstrated that 57 
anti-VEGF antibodies reduce oedema in the retina, in a substantial proportion 58 
of patients, but not all (12). This suggests that regulation of permeability 59 
during angiogenesis has multiple components (22). As a result, the 60 
therapeutic potential of other molecules, and especially those that act through 61 
lateral inhibition such as Delta-like ligand 4 (Dll4), has started to be explored 62 
(31).  63 
Dll4 is over-expressed in tumour vasculature (32) and, in tumour-bearing 64 
animals.  The use of a neutralising antibody has led to an inhibition of tumour 65 
growth (37), which was shown to be a consequence of non-productive 66 
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angiogenesis (31). Tumours treated with Dll4 inhibitors exhibited reduced 67 
pericyte coverage, increased vascular leakage and impaired vascular integrity 68 
(13) (24), which supported the rationale behind Dll4-targeted therapies for 69 
cancer treatment. It also hinted at a role for Dll4 in the maintenance of 70 
endothelial barrier integrity. More recently, targeting of delta-like 1 homologue, 71 
a tumour pericyte-associated antigen and Notch antagonist, has led to the 72 
development of combined vaccination approaches that lead to reduced 73 
vascular permeability and vascular normalization (11) (16). We therefore 74 
tested the hypothesis that Dll4 could control permeability of endothelial 75 
barriers in vitro and in vivo.   76 
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METHODS 77 
 78 
Cells, recombinant proteins and inhibitors  79 
Human dermal blood endothelial cells (HDBECs) were purchased from 80 
Promocell, cultured in EBM-2 complete media (Lonza) and maintained at 81 
37°C in a humidified chamber with 5% CO2. HUVECS were cultured and 82 
expanded in Endothelial Cell Basal Medium (PromoCell GmbH, Heidelberg, 83 
Germany). 84 
 85 
Recombinant human VEGF-A165a (40ng/mL), recombinant human sDll4 (aa 86 
27-524; 1μg/mL), the γ-secretase inhibitor N-[N-(3,5-Difluorophenacetyl)-L-87 
alanyl]-S-phenylglycine t-butyl ester (DAPT, Tocris BioScience), and N-[2-[[3-88 
(4-Bromophenyl)-2-propenyl]amino]ethyl]-5-isoquinolinesulfonamide 89 
dihydrochloride (H89), a PKA inhibitor (Tocris BioScience; 1μM) were used to 90 
both treat HDBECs or to perfuse mesenteric vessels in vivo. For knockdown 91 
experiments, 24 h prior to transfection HUVECs were seeded at 20,000 92 
cells/cm2.  For immunofluorescence, cells were cultured on coverslips coated 93 
with 0.2 % gelatin in PBS (Sigma Aldrich). Four different PKA siRNA (1-4, 94 
Table 1, Sigma-Aldrich) or scrambled siRNA were transfected using 95 
Oligofectamine (Invitrogen) at a final concentration of  200 nM in 100 µL 96 
OptiMEM (Gibco) as per manufacturers instructions.  97 
 98 
Quantitative RT-PCR 99 
RNA extraction was performed with TRI reagent (Sigma) and cDNA was 100 
generated using the Takara Prime script RT kit. Pre-validated primers for 101 
human genes Hairy/enhancer-of-split related with YRPW motif protein 1 102 
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(HES1, HEY1) and Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 103 
were purchased from Qiagen. Human β-Actin primers and human PKA 104 
primers were used as in Table 2.  PCR reactions were performed in triplicate 105 
with 10μl Lightcycler 480 SYBR Green 1 mastermix (Roche), 2μl primer sets, 106 
2μl cDNA and 8μl water.  Expression relative to control was calculated from 107 
the cycle thresholds (CT) and calculated as the difference between the test 108 
CT and the housekeeping gene (ΔCT) subtracted from the mean control 109 
sample ΔCT (ΔΔCT) and assuming doubling efficiency of 1 (2-ΔΔCT). 110 
 111 
Transwell assay 112 
Corning transwell inserts (6.5mm diameter, 0.4μm pore size) coated with 1% 113 
gelatin solution were used to seed HDBECs at a density of 5 x 104 cells/insert. 114 
Relative media volumes were 100μL in the insert and 600μL in the lower 115 
compartment to avoid changes in hydrostatic pressure. Once cells had 116 
become confluent, a FITC-Bovine Serum Albumin (BSA) solution (1mg/mL) 117 
was added to both compartments and treatments started after 30 minutes of 118 
equilibration. Samples of phenol-free media were taken from both 119 
compartments at 30 minute intervals and their absorbance read at 492/520nm 120 
absorption/emission.  121 
 122 
Immunofluorescence, staining and imaging 123 
Sterile 13mm2 coverslips coated with 0.2mg/cm2 fibronectin were used to 124 
plate 3 x 104 HDBECs, or 0.2% gelatin for HUVECs. The cells were incubated 125 
until a monolayer was formed and then treated for 4 hours with vehicle, VEGF 126 
or sDll4. The media was then discarded and the cells were fixed in ice-cold 127 
ethanol at -20°C for 30 minutes, washed in PBS and incubated at 4°C 128 
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overnight with rabbit polyclonal anti-activated Notch1 antibody (ab8925, 129 
Abcam; 1:200), polyclonal rabbit anti-VE Cadherin antibody (ab33168, 130 
Abcam; 5μg/ml) or polyclonal rabbit anti-ZO-1 antibody (ab59720, Abcam; 131 
10μg/ml). The following day, cells were washed and stained with donkey anti-132 
rabbit Alexa Fluor 555-conjugated antibody (Life Technologies; 1μg/ml) and 133 
phalloidin Alexa Fluor 488-conjugated (Life Technologies; 1:500). Nuclei were 134 
stained with DAPI and the coverslips were mounted onto microscope slides 135 
with anti-fade Vectashield. z-stack images of 5 regions from each coverslip 136 
were acquired with a confocal microscope at 40x magnification. Analysis was 137 
undertaken blinded using Image J analysis software. 138 
All in vitro experiments were performed in triplicate and repeated 3 times 139 
unless otherwise stated and the data are presented as mean ±SEM with the 140 
number of experimental independent replicates being the n number given and 141 
used for statistical analysis. Post-hoc power analysis indicates that all 142 
significant differences were achieved with a power greater than 80%. Power 143 
for non significant differences is given where stated. Power was calculated 144 
using G Power.  The percentage of thick and thin junctions and junctional 145 
gaps was statistically analysed using a two-way ANOVA with a Bonferroni 146 
post-test and fluorescence intensity for both VE-Cadherin and ZO-1 staining 147 
was statistically analysed using a one-way ANOVA with a Bonferroni post-148 
test. Both analyses used confidence intervals of 95%. 149 
 150 
Measurement of hydraulic conductivity (Lp) 151 
All animal experiments were conducted according to the Animal (Scientific 152 
Procedures) Act of 1986, according to UK legislation, and conducted in 153 
named establishments, under the authority of the Home Office. 154 
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Male Han Wistar rats (n=5 per group) were anaesthetized with 2% isoflurane 155 
vaporized in 100% O2 and a laparotomy was performed under sterile 156 
conditions. The mesentery was draped over a quartz pillar bathed in warmed 157 
mammalian Ringer’s solution and the animal moved to the imaging rig. A 158 
refillable glass micropipette was then used to cannulate a post-capillary 159 
venule and the vessel was continuously perfused with a solution of 1% bovine 160 
serum albumin (BSA, Sigma) in Ringer’s solution (pH=7.40). Washed red 161 
blood cells (RBCs) were used as flow markers and the vessel was occluded 162 
at 15-20 second intervals. After approximately 8 min, the pipette was refilled 163 
again with either the control BSA solution, sDll4 or the PKA inhibitor H89 164 
dihydrochloride (H89) and repeated occlusion of the vessel was continued. At 165 
the end of the experiment the animal was killed by cervical dislocation while 166 
still under anaesthesia. Video recordings of each vessel were analysed to 167 
calculate Lp. During each vessel occlusion, we measured the vessel radius, 168 
the distance between the occlusion site and a single RBC, and calculated its 169 
velocity; with this information, we calculated the transcapillary water flow per 170 
unit area (Jv/S), as previously described (39). Hydraulic conductivity (Lp) was 171 
then calculated as the slope of the relation between Jv/S and pressure. An 172 
unpaired t test was performed using the fold change compared to baseline 173 
maximal responses for BSA versus sDll4. A one-way ANOVA (with a 174 
Bonferroni post-test) was performed for comparison of maximal responses for 175 
sDll4 versus H89 and H89 + sDll4. Confidence levels were set at 95% and all 176 
data is presented as mean ±SEM.  177 
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RESULTS 178 
 179 
Soluble Delta-like ligand 4 (sDll4) activates Notch signalling in ECs  180 
To determine whether we could experimentally induce Dll4 forward signalling 181 
we used recombinant soluble Dll4 protein. In confluent cultured endothelial 182 
cells (ECs), Notch staining was diffuse and more abundant in the cytoplasm 183 
(Fig 1A), whereas treatment with either 1µg/ml sDll4 or 40ng/ml VEGF-A led 184 
to the appearance of punctate staining of Notch, indicating proteolytic 185 
cleavage of Notch to result in the release of Notch Intracellular Domain 186 
(NICD, fig 1A). Moreover, in cells treated with 1µg/ml sDll4, Notch staining 187 
tended to be localized inside the nucleus (see side projection in Fig 1B).  188 
To ascertain whether increased NICD translocation translates to induction of 189 
the translation of target genes, we compared levels of expression of Notch 190 
target genes Hes1 and Hey1. HDBECs were incubated until 80% confluent 191 
and then treated for 4 hours with vehicle (negative control), VEGF (positive 192 
control) or sDll4. Treatment of HDBECs with 1µg/ml sDll4 recombinant protein 193 
upregulates both Hes1 (Fig 1B) and Hey1 transcripts (Fig 1C), when 194 
compared with untreated cells, and at a level similar to that elicited by VEGF 195 
stimulation. Although this upregulation was more pronounced for Hey1 196 
(around 10-fold increase compared with untreated, Fig 1C) than for Hes1 197 
(around 2-fold increase compared with untreated, Fig 1B), it was completely 198 
abrogated by treatment with the γ-secretase inhibitor DAPT, both for Hes1 199 
and Hey1 (Fig 1B&C), indicating that sDll4-mediated signalling acts in a 200 
manner similar to the canonical understanding of Dll4-Notch1 signalling. 201 
 202 
sDll4 promotes endothelial junctional protein expression 203 
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To investigate the effects of Dll4-Notch signalling on vascular permeability we 204 
first investigated changes in junctional proteins. We treated EC monolayers 205 
with VEGF or sDll4 and stained the cells with phalloidin for cytoskeletal 206 
protein F-actin and VE-Cadherin for adherens junctions (Fig 2A) or ZO-1 for 207 
tight junctions (Fig 2B). sDll4 treatment led to a rearrangement of actin fibres 208 
in cultured ECs, which were located around the periphery of the cells 209 
compared with the parallel arrangement seen in untreated and VEGF-treated 210 
cells (Fig 2A). VE-Cadherin staining tended to be localized at EC-EC junctions 211 
in untreated cells (Fig 2A). Similarly, ZO-1 expression was enhanced by sDll4, 212 
but reduced by VEGF-A (Fig 2B). The VE-Cadherin positive junctions could 213 
be divided into a thick and thin morphology (Fig 2C). In untreated cells, the 214 
VE-Cadherin positive thin junctions formed the majority (54.5%) and the thick 215 
junctions account for only 20.9% of the total junctional length. Whereas VEGF 216 
caused no significant difference in the distributions of the types of adherens 217 
junctions compared to untreated cells, sDll4 significantly decreased the 218 
percentage of thin junctions and significantly increased the percentage of 219 
thick junctions (Fig 2C). VEGF treatment also resulted in the lowest number of 220 
ZO-1-positive junctions per cell (Fig 2D). Together, these results indicate that 221 
sDll4 leads to a rearrangement of the proteins comprising adherens junctions 222 
that could result in an improvement in the barrier function of EC monolayers.  223 
 224 
sDll4 improves endothelial barrier function in vitro  225 
Having established that sDll4 induced Notch signalling in a manner similar to 226 
VEGF, and that it could affect barrier protein expression in a manner opposite 227 
to VEGF, we assessed the effect of sDll4 on permeability of confluent cells. 228 
We used a transwell assay to measure the movement of FITC-labelled 229 
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albumin across a monolayer of ECs (Fig 3). Treatment of cells with 40ng/ml 230 
VEGF-A resulted in an increase in FITC-BSA in the lower well (Fig 3A). In 231 
contrast, 1µg/ml sDll4 reduced the FITC-BSA in the lower wells compared 232 
with control. We calculated the permeability of the monolayer, assuming 233 
negligible active transport or convection, based on the solute flux (mass of 234 
FITC-BSA that crossed the transwell per 30 minute time period), the area of 235 
the membrane and the concentration gradient at that time point. Fig 3B shows 236 
that sDll4 resulted in a transient decrease in permeability at 30 minutes 237 
compared with control. VEGF-A resulted in the characteristic biphasic 238 
increase in permeability. To determine whether the reduction in permeability 239 
by Dll4 was induced through Notch, we treated the cells with the γ-secretase 240 
inhibitor DAPT for 30 minutes prior to addition of the recombinant proteins to 241 
the media. This reversed the decrease in FITC-BSA transport (Fig 3C) and 242 
the decrease in permeability (Fig 3D). 243 
Mechanisms underlying decreased permeability are not well described. The 244 
most extensive literature on reduced permeability concerns the involvement of 245 
PKA signalling through cyclic adenosine monophosphate (cAMP) (1). We 246 
therefore investigated whether the PKA inhibitor H89 could reverse the 247 
decrease in permeability in HDBEC monolayers. Treatment of cells with 10µM 248 
H89 resulted in a significant increase in FITC-BSA in the lower well above 249 
vehicle control (Fig 3E). Treatment with sDll4 did not reduce the BSA-FITC 250 
concentration below control in the presence of H89, and after one hour there 251 
was more, not less FITC-BSA in the sDll4 treated wells than in the vehicle 252 
control. Calculation of permeability (Fig 3F) shows that the H89 baseline value 253 
was higher, and sDll4 did not reduce permeability in the presence of H89.  254 
 255 
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PKA inhibition impairs Notch signalling 256 
Dll4-Notch has not previously been shown to signal through PKA. Therefore, 257 
to determine whether downstream transcriptional activation of Notch target 258 
genes could be abrogated by treatment with H89, we measured Hey 259 
expression. We co-treated HDBEC with VEGF-A and DAPT or sDll4 and 260 
DAPT and obtained results similar to those reported earlier (Fig 1). Figure 3G 261 
also shows that when HDBEC are co-treated with DAPT or H89 262 
(concomitantly with VEGF-A or sDll4), they showed reduced Hey1 expression 263 
compared to vehicle. To confirm that PKA inhibition was behind the sDLL4 264 
mediated alteration in barrier function, HUVECs were transfected with four 265 
different PKA siRNA, or a combination of all four siRNA and cells stained for 266 
junctional proteins. All four siRNAs resulted in reduced expression of PKA, 267 
and combining all four resulted in a highly significant 77.1±1.6% reduction in 268 
RNA expression (Figure 4A). The DLL4 mediated increase in thick (fig 4B) 269 
and decrease in thin (figure 4C) junctions was blocked by PKA knockdown. 270 
PKA knockdown by itself also increased the number of gaps in the VE-271 
Cadherin stained junctions, but DLL4 again had no effect (Fig 4D). 272 
Interestingly, ZO1 staining was increased by PKA knockdown (fig 4E). These 273 
results confirm that activation of Notch signalling, both for its target genes and 274 
adherens junctional integrity, requires intact cAMP/PKA signalling. 275 
 276 
sDll4 reduces permeability to water in vivo 277 
To ascertain whether Dll4-Notch signalling resulted in a decrease in vascular 278 
permeability in vivo, we measured the effect of sDll4 on individually perfused 279 
microvessels of the intact rat mesentery. We used an intravital perfusion and 280 
microscopy system to cannulate and perfuse post-capillary venules in the 281 
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mesentery of anaesthetised rats. This enabled control of the oncotic and 282 
hydrostatic pressure gradients, expose cells to shear stress and rely on intact 283 
cell signalling. We used the Landis-Michel technique to measure hydraulic 284 
conductivity (Lp), where RBCs are used as flow markers (Fig 5). Control 285 
experiments showed that refilling of the cannulation pipette with 1% BSA 286 
solution did not change hydraulic conductivity (Fig 5A). In contrast, within 2 287 
minutes of perfusion with sDll4, Lp consistently began to fall below baseline, 288 
plateauing at a minimal value after 5 minutes, where it remained until the end 289 
of the experiment (~10 minutes, Fig 5B).  290 
 291 
sDll4-mediated decrease in Lp acts via cAMP/PKA 292 
To understand whether the mechanism underlying the reduction in 293 
permeability affected by sDll4 also depended on PKA, we perfused 294 
mesenteric post-capillary venules with H89. This led to a slight but not 295 
statistically significant increase in the hydraulic conductivity of these vessels 296 
(Fig 5C). When sDll4 and H89 were perfused together, Lp changed in a 297 
manner similar to H89 perfusion (Fig 5D), not sDll4, making the difference in 298 
Lp a very significant increase compared to sDll4 alone (Fig 5E). These results 299 
clearly demonstrate that, in vivo, sDll4 is acting through a cAMP/PKA 300 
dependent pathway to regulate microvessel permeability. 301 
  302 
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DISCUSSION 303 
 304 
The upregulation of the Notch ligand, Dll4 (27) is a downstream consequence 305 
of VEGF signalling through VEGF receptor 2 (VEGFR2). The subsequent 306 
paracrine reciprocal interaction of Dll4 with Notch has been recognized as the 307 
principal molecular mechanism giving rise to the tip or stalk cell phenotypes in 308 
sprouting angiogenesis (20) (41). Dll4 will bind to Notch on an adjacent EC 309 
membrane, leading to the γ-secretase mediated proteolytic cleavage of Notch 310 
and the subsequent release of the Notch Intracellular Domain (NICD) (10). 311 
The NICD translocates to the nucleus where it interacts with recombination 312 
signal binding protein for immunoglobulin kappa J region (RBPJ-κ). Upon 313 
binding, allosteric changes occur in RBPJ-κ which enable the displacement of 314 
transcriptional repressors and the subsequent transcription of Notch target 315 
genes such as Hes1 and Hey1 (19). Dll4/Notch signalling then negatively 316 
regulates VEGFR2 expression (41) with Notch playing an essential part in 317 
vascular plexus remodelling and maturation (14). To validate our experimental 318 
approach, we compared the effect of VEGF with the extracellular portion of 319 
Dll4 (sDll4) and found that sDll4 is sufficient to activate Notch signalling (Fig 320 
1). 321 
During sprouting angiogenesis, VE-Cadherin, the principal component of 322 
endothelial adherens junctions, is expressed on the anterior plasma 323 
membrane and in filopodia protrusions of tip cells (3). However, the continual 324 
flux in Notch levels in individual EC results in differential VE-cadherin turnover 325 
and junctional-cortex protrusions (8), which powers differential cell movement 326 
when EC compete for the tip cell position, first described in embryoid bodies 327 
(21). Thus, Dll4/Notch signalling at EC-EC junctions seems to play an 328 
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essential role in maintaining endothelial barrier integrity, especially during 329 
angiogenesis. Inhibition of γ-secretase with DAPT leads to inhibition of 330 
Dll4/Notch signalling (Fig 1) but it also has effects on other transmembrane 331 
proteins. In breast cancer cells, DAPT blocks E-cadherin cleavage (46). In 332 
cultured hippocampal neurons, endoplasmic reticulum loss was inhibited by 333 
DAPT, and this correlates with proteolytic activity affecting adherens junctions 334 
(29). In a rat model of permanent middle cerebral artery occlusion, DAPT 335 
reduced the permeability of the blood brain barrier by decreasing the 336 
ubiquitination and degradation of occludin (47). However, when we tested the 337 
effect of sDll4 in confluent cultured endothelial cells, we found that sDll4-338 
treated ECs undergo a change in expression and distribution of proteins that 339 
constitute adherens junctions, but not those involved in tight junctions (Fig 2), 340 
and reduces permeability in intact quiescent blood vessels. This suggests that 341 
previously described reduction in permeability by inhibition of the Notch 342 
pathway may be context dependent (active or confluent ECs) and tissue 343 
dependent (blood brain barrier compared with systemic capillaries). 344 
cAMP has been shown to stabilise the endothelial barrier by reducing myosin 345 
light chain phosphorylation (45) (9), inhibiting the GTPase RhoA (34), 346 
preventing Rac1 inhibition (43) and acting through Epac/Rap1 to stabilise 347 
cortical actin (2), leading to an increase in cytoskeletal-associated VE-348 
Cadherin. Here, we add to this knowledge by showing that sDll4 decreases 349 
solute flux across an endothelial cell monolayer and this is reversed by H89, 350 
an inhibitor of PKA (Fig 3), and that this PKA mediated re-arrangement 351 
controls adherens junctional formation (but not tight junctional components 352 
such as ZO1). This indicates that PKA-dependent cAMP signalling mediates 353 
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DLL4 mediated VE-Cadherin assembly at adherens junctions and promotes 354 
endothelial barrier integrity. 355 
Recently, the link between VE-Cadherin and Dll4/Notch signalling has been 356 
further explored (33). Using an engineered blood vessel model, the authors 357 
found that a novel LAR/Trio/Rac1 complex is formed due to Notch “non-358 
canonical” signalling to drive assembly of adherens junctions, in response to 359 
shear stress. Rac1 has been shown to be downstream of cAMP, in thrombin 360 
induced permeability enhancement in ECs (4). In the present paper, we 361 
further add to the mechanistic insight into Dll4/Notch mediated reduction in 362 
permeability, finding that this non-canonical signalling is through cAMP-363 
mediated activation of PKA, which causes a reduction in barrier function, 364 
presumably through phosphorylation of Rac1, allowing it to facilitate the 365 
interaction between the Lar-Notch1 TMD-VE-Cadherin complex through the 366 
GEF-Trio axis (Fig 6). Further we show here that this results in an actual 367 
decrease in permeability of the barrier wall in vivo (Fig 5), rather than just a 368 
reduction in solute flux, which could be explained by haemodynamic changes.  369 
Over the years, a number of papers have linked the formation of 370 
mechanosensing complexes with endothelial barrier function (42) (17). What 371 
was once thought of as arterial specification during development may be 372 
mechanistically linked to sensing of shear stress (23). Indeed, low shear 373 
stress-induced atherosclerotic plaque formation was inhibited by DAPT, with 374 
the subsequent downregulation of NICD and ICAM-1 (35). This may not be 375 
limited to ECs, since pericyte-derived Dll4 may control involution of infantile 376 
haemangioma in a VEGF-independent manner (23). Of interest was the 377 
distinguishment of tight junctional protein rearrangement from adherens 378 
junctions (figs 2 and 4). Whereas sDLL4 did not affect ZO1 expression, PKA 379 
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knockdown increased it, which was blocked by sDLL4. This indicates that 380 
there are two different mechanisms for regulating permeability through the two 381 
different pathways. This could be due to localization of PKA to the different 382 
junctional compartments, a mechanism proposed by Radeva et al to be 383 
mediated by AKAP12(36). 384 
 In summary, we show here for the first time that Dll4 mediated 385 
activation of Notch can reduce hydraulic conductivity, and hence the 386 
permeability of the capillary wall, through activation of cAMP. This supports 387 
the concept that fluid and solute exchange is limited in normal vasculature by 388 
Notch signalling through regulation of adherens junctions.  389 
 390 
391 
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FIGURE LEGENDS 404 
 405 
Figure 1: sDll4 promotes Notch intracellular signalling in endothelial 406 
cells. A) Representative confocal images of HDBECs which were treated with 407 
VEGF, sDll4 or vehicle control and then stained for Notch 1 (red) and 408 
phalloidin (green) with nuclear counterstain for Hoechst (blue) reveal nuclear 409 
localization and punctate staining of Notch 1 upon VEGF or sDll4 treatment. 410 
B. Z projection of cells demonstrating nuclear (blue arrow) expression of 411 
Notch 1 (red arrow) in sDLL4 and VEGF treated cells, but not in vehicle 412 
treated cells.  Scale bar=25μm. VEGF and sDll4 treatment result in 413 
indistinguishable increase in the expression of Notch 1 target genes C) Hes 1 414 
and D) Hey 1 relative to vehicle, as assessed by ddPCR; this upregulation in 415 
RNA transcription is impaired by co-treatment of HDBECs with DAPT. 416 
 417 
Figure 2: sDll4 promotes the re-arrangement of adherens junctions. 418 
Representative confocal images of HDBECs which were treated with VEGF, 419 
sDll4 or vehicle control and then stained for phalloidin (green) and A) VE-420 
Cadherin for adherens junctions (red) or B) ZO-1 for tight junctions (red) with 421 
nuclear counterstain for DAPI (blue). Scale bar=25μm. Image analysis was 422 
performed using FIJI to quantify C) the percentage of intercellular space 423 
occupied by gaps or VE-Cadherin-positive intercellular junctions between 424 
cells and D) the number of ZO-1-positive junctions per cell. VEGF treatment 425 
led to an increase in the number of gaps and decrease in the number of 426 
junctions per cell, whilst sDll4 promoted the formation of thicker adherens 427 
junctions. **p<0.01; ***p<0.005; ****p<0.001, two-way ANOVA with 95% CI 428 
and Bonferroni post-test. 429 
 430 
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Figure 3: sDll4 decreases endothelial monolayer permeability via cAMP. 431 
A) In EC monolayers, the flux of FITC-labelled BSA reaches 4μg/mL after 2 432 
hours (N=6), whereas, in the presence of VEGF165a, it increases to over 433 
10μg/mL (N=8). sDll4 decreases FITC concentration to below that of vehicle, 434 
and significantly below VEGF (N=8). B) This translates in a typical biphasic 435 
response for VEGF permeability, that is counter-acted in a mirroring 436 
behaviour by the effect of sDll4 on the EC monolayer. C) Inhibition of sDll4 437 
(N=5) with DAPT (N=5) increases FITC concentration and D) permeability 438 
above vehicle. E) PKA inhibition with H89 resulted in increased permeability 439 
above vehicle (N=3), which was not impaired by sDll4 (N=3); in effect, F) 440 
permeability was the same for H89 and sDll4+H89. G) Both DAPT and H89 441 
were able to abolish both VEGF and sDll4-mediated increases in Hey1 gene 442 
expression (N=3 per group). P<0.001 ANOVA with Bonferroni post-test. 443 
***=p<0.001 compared with vehicle. #=p<0.05 compared with DAPT, 444 
++=p<0.01 compared with H89. ANOVA with Bonferroni post-test. 445 
 446 
Figure 4. Formation of adherens junctions by DLL4 is PKA dependent. 447 
A) Knockdown of PKA using four different PKA siRNAs. Cells were treated 448 
with the siRNA and RNA extracted and amplified by Q-PCR after 48 hours. 449 
N=3 HUVECs were stained for VE-Cadherin and ZO-1 and junctional type 450 
calculated as in figure 2. The increase in thick junctions (B) and decrease in 451 
thin junctions (C) was blocked by PKA knockdown. PKA knockdown 452 
increased the percentage of gaps (D), in the absence but not the presence of 453 
sDLL4. E) ZO1 junctional staining was increased by PKA knockdown in the 454 
absence but not the presence of sDLL4. *=p<0.01, **=p<0.01, ***=p<0.001 455 
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compared with scrambled control. ##=p<0.01 compared with sDLL4. B-E, 456 
N=5 ANOVA with Bonferroni post-test. 457 
 458 
Figure 5: sDll4 decreases hydraulic conductivity in vivo via a 459 
cAMP/PKA-dependent pathway. Calculation of hydraulic conductivity (Lp) in 460 
post-capillary venules of the mesentery of rats revealed that A) reperfusion 461 
with BSA does not alter vascular permeability (N=5). B) Perfusion with sDll4 462 
showed a clear decrease in permeability compared to BSA within 120 463 
seconds until it plateaued at 300 seconds (N=5). Whilst C) H89 perfusion had 464 
no effect in water permeability relative to BSA baseline (N=5), D) perfusion 465 
with the combination of H89 and sDll4 did not result in a change in Lp despite 466 
constant fluctuations around baseline (N=5). E) Relative to BSA vehicle, peak 467 
response in sDll4 gave rise to around 60% decrease in water permeability, 468 
which was completely abrogated by H89. P<0.001 ANOVA with Bonferroni 469 
post-test. ***=p<0.001 compared with BSA. +++=p<0.001 compared with 470 
DLL4+H89 471 
 472 
Figure 6. Schematic for the junctional regulation of VE-Cadherin by Dll4-473 
Notch signalling. The endothelial cells, covered by a layer of glycocalyx, 474 
forms an intercellular cleft where two endothelial cells meet. The cleft contains 475 
adherens junctions, and tight junctions (not shown). The AJ consist of VE-476 
Cadherin bound to multiple signalling molecules (not shown). Upon activation 477 
of Notch by Dll4, cAMP is generated, either directly or indirectly, which results 478 
in strengthening of the VE-Cadherin junctions. Recent work by Polacheck et 479 
al has shown that the transmembrane domain of Notch can bind to Lar-Trio-480 
Rac1 complex, which is known to be activated by phosphorylation by PKA.  481 
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Table 1. siRNA sequences. 483 
siRNA SEQUENCE 5'-3' 
PKA1F GAACACACCCUGAAUGAAAUU  
PKA1F AS UUUCAUUCAGGGUGUGUUCUU 
    
PKA2F GAACACAGCCCACUUGGAUUU 
PKA2FAS AUCCAAGUGGGCUGUGUUCUU 
    
PKFA3F CAAGGACAACUCAAACUUAUU  
PKFA3FAS UAAGUUUGAGUUGUCCUUGUU 
    
PKFA4 GCUAAGGGCAAAUGAACGAUU 
PKA4FAS UCGUUCAUUUGCCCUUAGCUU 
 484 
Table 2. Primer sequences and sources 485 
Primer Source Sequence Catalogue 
number 
Hes 1.  Qiagen  Not disclosed by supplier QT00039648 
Hey 1.  Qiagen  Not disclosed by supplier QT00035644  
GAPDH Qiagen Not disclosed by supplier QT00079247 
Actin fwd Qiagen  5’CCCAGCACAATGAAGATCAA3’  
Actin rev Qiagen 5’CGATCCACACGGAGTACTTG3’  
PKA fwd Qiagen  5’GAAGATCGTCTCTGGGAAGT3’  
PKA rev Qiagen 5’TGACCCCATTCTTGAGGTTC3’  
 486 
487 
 24
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